Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies.

@article{Gerber2005PharmacologyAP,
  title={Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies.},
  author={H P Gerber and Napoleone M. A. Ferrara},
  journal={Cancer research},
  year={2005},
  volume={65 3},
  pages={671-80}
}
Preclinical models have examined the pharmacologic and pharmacodynamic activities of an anti-vascular endothelial growth factor (VEGF) humanized, monoclonal antibody, bevacizumab, and/or its murine equivalent A4.6.1. These studies found that single-agent therapy with bevacizumab/A4.6.1 resulted in tumor growth inhibition of 20 different human tumor cell lines (13 tumor types) implanted into nude mice irrespective of the route of administration or tumor location. Several of these studies also… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 233 extracted citations

Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy

Journal of hematology & oncology • 2012
View 3 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 84 references

Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor

CD Pham, TP Roberts, N van Bruggen
Cancer Invest 1998;16:225–30 • 2005
View 1 Excerpt

Addition of bevacizumab (rhuMAb VEGF) to bolus IFL in the first-line treatment of patients with metastatic colorectal cancer: results of a randomized phase III trial

HI Hurwitz, L Fehrenbacher, W Novotny
N Engl J Med • 2004
View 2 Excerpts

Similar Papers

Loading similar papers…